CMTM6 and cancer: It has been shown that the number of genetic mutations in patients [75], the presence of CMTM6 molecules [76], CD28/B7 status [77], and intestinal microbes [78] may be associated with new antigens on the surface of cancer cells, PD-L1 half-life, T cell activity, and T cell recruitment, respectively.